C.T. Fitzpatrick
Vulcan Value Partners
Vulcan Value Partners Abbott Laboratories stake
total: 273
Vulcan Value Partners ABT trades
- Total transactions:
- 12
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 7
- Held since:
- 2022 Q4
- Held for:
- 9 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q2 report, Vulcan Value Partners doesn't hold any Abbott Laboratories (ABT) shares. To date, the estimated cost basis is nearly $109.7 for "buy" trades and estimated average "sell" price is $110.01. Vulcan Value Partners first purchased ABT in 2014 Q2, initially acquiring 785 shares. Vulcan Value Partners later completely sold out the position and invested in Abbott Laboratories again in 2022 Q4. Since the initial investment in Abbott Laboratories (ABT), Vulcan Value Partners has made 11 more transactions.
When did Vulcan Value Partners sell Abbott Laboratories (ABT)?
Vulcan Value Partners sold off the entire Abbott Laboratories (ABT) position in 2025 Q1.
When did Vulcan Value Partners buy Abbott Laboratories (ABT)?
Vulcan Value Partners first invested in Abbott Laboratories (ABT) in 2014 Q2 at the reported quarter-end price of $40.76 per share.
What's the cost basis of Vulcan Value Partners's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $109.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $109.70
- Weighted AVG sell price:
- $110.01
Vulcan Value Partners's historical trades in Abbott Laboratories
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$113.14
|
|
-100% (-370,518)
|
-0.7%
|
|
2024 Q4
|
0.70%
|
370,518
|
$113.14
|
$41,919,956
|
-4.54% (-17,604)
|
-0.03%
|
|
2024 Q3
|
0.74%
|
388,122
|
$114.01
|
$44,249,789
|
-22.45% (-112,347)
|
-0.19%
|
|
2024 Q2
|
0.79%
|
500,469
|
$103.86
|
$51,978,000
|
-11.93% (-67,791)
|
-0.1%
|
|
2024 Q1
|
0.94%
|
568,260
|
$113.56
|
$64,530,000
|
-14.56% (-96,828)
|
-0.16%
|
|
2023 Q4
|
1.07%
|
665,088
|
$110.06
|
$73,198,000
|
-8.41% (-61,077)
|
-0.1%
|
|
2023 Q3
|
1.07%
|
726,165
|
$96.79
|
$70,283,000
|
-13.65% (-114,821)
|
-0.14%
|
|
2023 Q2
|
1.15%
|
840,986
|
$108.92
|
$91,602,000
|
-7.21% (-65,321)
|
-0.09%
|
|
2023 Q1
|
1.16%
|
906,307
|
$101.28
|
$91,793,000
|
+0.94% (+8,444)
|
+0.01%
|
|
2022 Q4
|
1.32%
|
897,863
|
$109.78
|
$98,563,000
|
new
|
+1.32%
|
|
2014 Q3
|
0.00%
|
$40.76
|
-100% (-785)
|
|||
|
2014 Q2
|
0.00%
|
$40.76
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.